Literature DB >> 22430086

Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation.

Shigeo Fuji1, Fumiaki Nakamura, Kazuo Hatanaka, Shuichi Taniguchi, Maho Sato, Shin-Ichiro Mori, Hisashi Sakamaki, Hiromasa Yabe, Toshihiro Miyamoto, Heiwa Kanamori, Yasunori Ueda, Keisei Kawa, Koji Kato, Ritsuro Suzuki, Yoshiko Atsuta, Toshiharu Tamaki, Yoshinobu Kanda.   

Abstract

To compare the different stem cell sources used in salvage transplantation for graft failure (GF) after cord blood transplantation (CBT), we retrospectively analyzed data of 220 patients who developed GF after undergoing CBT between January 2001 and December 2007 and underwent a second hematopoietic stem cell transplantation (HSCT) within 3 months. The donor sources for salvage HSCT were cord blood (n = 180), peripheral blood stem cells (PBSCs; n = 24), and bone marrow (BM; n = 16). The cumulative incidence of neutrophil engraftment on day 30 after the second HSCT was 39% with CB, 71% with PBSCs, and 75% with BM. Multivariate analysis revealed that PBSC and BM grafts were associated with a significantly higher engraftment rate than CB (hazard ratio [HR], 7.77; P < .001 and HR, 2.81; P = .016, respectively). Although the incidence of grade II-IV acute graft-versus-host disease was significantly higher in the PBSC group than in the CB group (HR, 2.83; P = .011), the incidence of 1-year nonrelapse mortality was lower in the PBSC group than in the CB group (HR, 0.43; P = .019), and 1-year overall survival was superior in the PBSC group compared with the CB group (HR, 0.45; P = .036). Our results suggest that PBSC is the preferable source of stem cells in salvage HSCT for GF after CBT.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22430086     DOI: 10.1016/j.bbmt.2012.02.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  11 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.

Authors:  K Ishiyama; J Takeda; T Kondo; N Sugimoto; H Kawabata; T Kitano; A Takaori-Kondo
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

3.  Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; J Tong; B-L Tang; C-Y Zhou; W Yao; C-C Zheng; K-D Song; X-Y Zhu; W Wei; Y Wang
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

4.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

5.  Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Authors:  Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

6.  Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells.

Authors:  M Kwon; C Martínez-Laperche; P Balsalobre; D Serrano; J Anguita; J Gayoso; J L Díez-Martín; I Buño
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

7.  Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Authors:  D E Gladstone; M Petri; J Bolaños-Meade; A E Dezern; R J Jones; D Fine; R A Brodsky
Journal:  Lupus       Date:  2016-09-30       Impact factor: 2.911

8.  Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Shigeo Fuji; Sachiko Seo; Junya Kanda; Toshimitsu Ueki; Fumihiko Kimura; Koji Kato; Naoyuki Uchida; Kazuhiro Ikegame; Makoto Onizuka; Ken-Ichi Matsuoka; Noriko Doki; Toshiro Kawakita; Yasushi Onishi; Shingo Yano; Takahiro Fukuda; Minoko Takanashi; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata
Journal:  Bone Marrow Transplant       Date:  2020-02-12       Impact factor: 5.483

9.  A novel three-dimensional flow chamber device to study chemokine-directed extravasation of cells circulating under physiological flow conditions.

Authors:  Valentina Goncharova; Sophia K Khaldoyanidi
Journal:  J Vis Exp       Date:  2013-07-15       Impact factor: 1.355

10.  Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure.

Authors:  Cristina Tecchio; Angelo Andreini; Claudio Costantini; Alberto Zamò; Donata de Sabata; Fiorenza Aprili; Roberta Galavotti; Emanuele Guardalben; Fabio Benedetti
Journal:  Hematol Rep       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.